Sakar Healthcare Q3 FY26 results: Revenue up 62%, PAT jumps 126% YoY
SAKAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.0 pts more than Nifty Microcap 250 and 6.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sakar Healthcare reported Q3 FY26 standalone revenue of Rs 70.34 crore, up 62% YoY from Rs 43.42 crore. Profit after tax surged 126% YoY to Rs 10.25 crore from Rs 4.53 crore. For 9M FY26, revenue grew 42% to Rs 180.64 crore and PAT rose 66% to Rs 19.46 crore. EPS stood at Rs 4.59 vs Rs 2.08. Results are unaudited and reviewed by statutory auditor J.S. Shah & Co.
Strong top-line and bottom-line growth with margin improvement; positive for shareholders. Monitor sustainability of growth momentum.